Imago BioSciences (Imago BioSciences) Cash And Cash Equivalents : $7.29 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Imago BioSciences Cash And Cash Equivalents?

Imago BioSciences's quarterly cash and cash equivalents increased from Mar. 2022 ($8.26 Mil) to Jun. 2022 ($22.77 Mil) but then stayed the same from Jun. 2022 ($22.77 Mil) to Sep. 2022 ($7.29 Mil).

Imago BioSciences's annual cash and cash equivalents increased from Dec. 2019 ($4.96 Mil) to Dec. 2020 ($19.27 Mil) but then declined from Dec. 2020 ($19.27 Mil) to Dec. 2021 ($11.23 Mil).

Imago BioSciences Cash And Cash Equivalents Historical Data

The historical data trend for Imago BioSciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imago BioSciences Cash And Cash Equivalents Chart

Imago BioSciences Annual Data

Trend

Dec19

Dec20

Dec21

Cash And Cash Equivalents

4.96

19.27

11.23

Imago BioSciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash And Cash Equivalents	Get a 7-Day Free Trial							85.21	11.23	8.26	22.77	7.29

Imago BioSciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Imago BioSciences (NAS:IMGO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Imago BioSciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Imago BioSciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Imago BioSciences (Imago BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imago BioSciences Inc (NAS:IMGO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA, USA, 94080

Website

https://www.imagobio.com

Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).

Executives

Laura G. Eichorn	officer: Chief Operating Officer	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Michael Arenberg	officer: See Remarks	10260 BUBB ROAD, CUPERTINO CA 95014
Hugh Jr Rienhoff	director, officer: Chief Executive Officer	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Amy E. Tapper	officer: See Remarks	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Jennifer Peppe	officer: See Remarks	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Hsiangyi Chiang	officer: Senior Vice President Finance	C/O IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c.	10 percent owner	C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Clarus Ventures Iii Gp, L.p.	10 percent owner	C/O CLARUS VENTURES, 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Iii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Group Management L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings I/ii Gp L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings Ii L.p.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142